The results indicated that the key targets of the pathway in cancer were related to the therapeutic effect of anti-liver cancer activities, including SRC, EGFR, ESR1, PTGS2, and APP (Yan et al., 2011; Ren et al., 2016; Di Stadio et al., 2017; Markosyan et al., 2019; Hunter et al., 2020; Yuan et al., 2021). The gene discussed is PTGS2; the disease is cancer.